Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance

Antimicrob Agents Chemother. 2012 Dec;56(12):6393-6. doi: 10.1128/AAC.01421-12. Epub 2012 Sep 24.

Abstract

We investigated the frequency and clinical significance of macrolide resistance in adult and pediatric patients with community-acquired pneumonia from a Mycoplasma pneumoniae infection. The frequency of the A2063G mutation in the 23S rRNA gene was significantly higher in children than in adults (61.3% [19/31] and 13.3% [8/60], respectively; P < 0.001). Patients with macrolide-resistant M. pneumoniae infections showed a longer duration of fever (P = 0.021) and required a longer duration of antibiotic treatment (P = 0.007).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Child, Preschool
  • Community-Acquired Infections / drug therapy
  • Community-Acquired Infections / genetics*
  • Community-Acquired Infections / microbiology*
  • DNA / genetics
  • Drug Resistance, Bacterial / genetics*
  • Female
  • Humans
  • Infant
  • Macrolides / pharmacology*
  • Macrolides / therapeutic use
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Mutation
  • Mycoplasma pneumoniae / drug effects*
  • Mycoplasma pneumoniae / genetics*
  • Nasopharynx / microbiology
  • Pneumonia, Mycoplasma / drug therapy
  • Pneumonia, Mycoplasma / genetics*
  • Pneumonia, Mycoplasma / microbiology*
  • Polymerase Chain Reaction
  • RNA, Ribosomal, 23S / genetics*
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Macrolides
  • RNA, Ribosomal, 23S
  • DNA